Too much AKT turns PAX3-FKHR dead: A prospect of novel therapeutic strategy for alveolar rhabdomyosarcoma

Oncotarget

Volumn 3, Issue 10, 2012, Pages 1064-1065

  Jothi, Mathivanan ^a   Mal, Asoke K ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; MYOD PROTEIN; PROTEIN KINASE B; RAPAMYCIN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CANCER PROGNOSIS; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CHROMOSOME TRANSLOCATION; EDITORIAL; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; METASTASIS; METASTATIC MELANOMA; MOLECULAR MODEL; NONHUMAN; PHENOTYPIC VARIATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RHABDOMYOSARCOMA; SEQUENCE ANALYSIS; SOFT TISSUE SARCOMA; SOLID TUMOR;

EID: 84872783337     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.713     Document Type: Editorial

References (10)

1. De Giovanni C, Landuzzi L, Nicoletti G, et al. Future Oncol 2009; 5:1449-75.
2. Jothi M, Nishijo K, Keller C, et al. Cell Cycle 2012; 11:895-908.
3. Zeng FY, Dong H, Cui J, et al. Biochemical and biophysical research communications 2010; 391:1049-55.
4. Toker A, Yoeli-Lerner M. Cancer research 2006; 66:3963-6.
5. Hutchinson JN, Jin J, Cardiff RD, et al. Cancer research 2004; 64:3171-8.
6. Gorlick R, Maris JM, Houghton PJ, et al. Pediatric blood & cancer 2012; 59:518-24.
7. Dilling MB, Dias P, Shapiro DN, et al. Cancer research 1994; 54:903-7.
8. Wan X, Harkavy B, Shen N, et al. Oncogene 2007; 26:1932-40.
9. van Horssen R, Ten Hagen TL, Eggermont AM. The oncologist 2006; 11:397-408.
10. Tamburini J, Elie C, Bardet V, et al. Blood 2007; 110:1025-8.